PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
01-Oct-2024 Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers Tessellate BIO
01-Oct-2024 DULAS’S NEW REFRIGERATION RANGE ADDRESSES STAGGERING VACCINE LOSSES CAUSED BY COLD CHAIN FAILURES Dulas Life Sciences
01-Oct-2024 PureTech to Present at CHEST 2024 Annual Meeting PureTech Health
01-Oct-2024 How to Find the Best Clinical Research Course for Your Career Goals Fusion technology solutions
30-Sep-2024 Decoding the Phases of Clinical Trials: From Concept to Market Fusion technology solutions
30-Sep-2024 Anticancer Drugs Market Growth Fueled by Advancements in Personalized Medicine Pristine Market Insights
30-Sep-2024 CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review CluePoints
27-Sep-2024 Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Sanofi
27-Sep-2024 CQDM and Epitopea Fund the Development and Validation of CryptoMapTM, a Platform Enabling the Development of RNA-based Immunotherapies Epitopea
27-Sep-2024 LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting LEO Pharma A/S
27-Sep-2024 Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia
27-Sep-2024 Bayer News - AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies Bayer AG
27-Sep-2024 OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease OMEICOS
27-Sep-2024 PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases PolTREG S.A.
25-Sep-2024 Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion
25-Sep-2024 New data show Almirall´s EBGLYSS® (lebrikizumab) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis Almirall
25-Sep-2024 Arctoris announces strategic partnership with Alphabet company, Isomorphic Labs Arctoris
25-Sep-2024 Univo IRB Launches Canadian Research Ethics Board Review Services for Clinical Trials in North America Univo IRB
25-Sep-2024 Coave Therapeutics to Present Novel Data Highlighting the Potential of its ALIGATER™ Platform to Enhance the Targeted Delivery of Genetic Medicines at Upcoming Conferences Coave Therapeutics
25-Sep-2024 Combination treatment improves response to immunotherapy for lung cancer Francis Crick Institute